Healthcare Innovators
Pharma pipelines and the payer that prices them.
HLTHXConviction weightedBalancedRebalanced quarterly5 holdings
Sample data. Price history on this build is generated from a seeded model, not a live feed, so levels and returns are illustrative. Constituents, weights, index maths and fee logic are real.
Performance
Level
81.42
−18.58%
over 6M
Rebased to 100 on Jan 2, 2026
Risk and return
Volatility13.6%Annualised
Max drawdown-26.3%Peak to trough
Return / risk-2.13Excess over 4.2% cash
Blended yield2.22%Weighted dividend
Return over risk is computed against a 4.2% risk-free rate. Below zero means the index has not paid for the volatility it carried in this window.
Composition
5Holdings
- Healthcare100.0%
ModerateTop weight 30.0% · behaves like 4.6 equal names
Constituents
- LLYEli Lilly−2.3pt30.0%
- UNHUnitedHealth Group−0.0pt22.0%
- JNJJohnson & Johnson+1.4pt18.0%
- ABBVAbbVie+2.1pt18.0%
- MRKMerck & Co−1.1pt12.0%
The rule
Conviction weighted
Weights are set by the index author rather than by a formula. Highest expression of a view, highest concentration risk.
Thesis
Large-cap pharmaceutical franchises with active late-stage pipelines, paired with the dominant managed-care operator. Lower correlation to the technology complex than anything else on the platform.
- Rebalance
- Quarterly
- Inception
- Jan 2, 2026
What an allocation buys
| Ticker | Weight | Price | Units | Value |
|---|---|---|---|---|
| LLY | 30.0% | $894.60 | 3.3535 | $3,000.00 |
| UNH | 22.0% | $342.10 | 6.4309 | $2,200.00 |
| JNJ | 18.0% | $172.80 | 10.4167 | $1,800.00 |
| ABBV | 18.0% | $214.50 | 8.3916 | $1,800.00 |
| MRK | 12.0% | $98.40 | 12.1951 | $1,200.00 |
Units are fractional by design — stock tokens are ERC-20s with 18 decimals, so weights resolve exactly at any allocation size rather than being rounded to whole shares.